Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 88c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022 4:05 PM ESTSignificant progress made increasing global patient access to sotrovimab;Â approximately 1.7 million doses sold to date
$917.2 million of sotrovimab collaboration revenue recognized in 2021
Multiple commercial and clinical value drivers expected across the portfolio in 2022
SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.
2021 was a transformative year in which we delivered our first blockbuster medicine,... More
